CALCA and migraine disorder: Tanei and Saito (2024), aiming to evaluate the real-world clinical results of anti-calcitonin gene-related peptide monoclonal antibody (CGRP mAb) treatment for migraine with MOH without abrupt drug discontinuation and no hospitalization, demonstrated successful outpatient management of MOH using CGRP mAbs without requiring hospitalization or abrupt medication discontinuation.8This approach offers several advantages: a) improved treatment adherence, b) reduced impact on daily activities, c) better patient acceptance of therapy, and d) lower risk of withdrawal symptoms.